ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

Gao, Mengqi; Lin, Yi; Liu, Xing; Li, Yiming; Zhang, Chuanbao; Wang, Zheng; Wang, Zhiliang; Wang, Yulin; Guo, Zongze

To further investigate the clinical significance of ISG20 in glioma, we analyzed the expression of ISG20 according to the World Health Organization (WHO) classification and molecular subtypes. We found that ISG20 expression level increased with increasing tumor grade (Figure 2(a); Fig. S1A ). The mesenchymal subtype of GBM showed the highest ISG20 expression level compared with the other subtypes, whereas the proneural subtype had the lowest ISG20 level (Figure 2 (b); Fig. S1B ). Moreover, ISG20 expression was up-regulated in 1p/ 19q-non-co-deleted gliomas compared with those with 1p/19qco-deletion (Figure 2(c); Fig. S1C ). In addition, ISG20 expression was significantly higher in IDHwt tumors compared with IDHmut tumors across all tumor grades (Figure 2 (d-f), Fig. S1D-F) . Overall, these results suggest that ISG20 expression is suppressed in IDH mutant tumors and is associated with higher tumor malignancy.